Recombinant canarypox virus vaccine co-expressing ...



Title Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep
Author(s) Josh D. Boone, Udeni B. Balasuriya, Kemal Karaca, Jean-Christophe Audonnet, Jiansheng Yao, Ling He, Robert Nordgren, Federica Monaco, Giovanni Savini, Ian A. Gardner, N. James MacLachlan
Journal Vaccine
Date 2007
Volume 25
Issue 4
Start page 672
End page 678
Abstract We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n=6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40–160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n=5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines.
DOI 10.1016/j.vaccine.2006.08.025

Using APA 6th Edition citation style.

[Page generation failure. The bibliography processor requires a browser with Javascript enabled.]

Times viewed: 473

Adding this citation to "My List" will allow you to export this citation in other styles.